Newtree뉴트리

Newtree's revenue has fallen for several years and it is now loss-making at the operating line, though its share price trades near a low multiple of book value.

Newtree is a KOSDAQ-listed Korean health functional food and inner-beauty company that sells through home shopping, online and offline channels. Trailing twelve-month revenue to H1 2026 was about ₩104B, with an operating loss of about ₩3.3B and a net profit of about ₩4.8B, while free cash flow was negative at about -₩9.0B. The share price is down about 30% over the past year and trades at a price-to-book ratio of 0.3.

What stands out

• Revenue fell 17.1% in 2025 to about ₩101B, continuing a decline from roughly ₩248B in 2021.
• Operating income swung from a ₩10.5B profit in 2023 to losses in 2025 and in the trailing period to H1 2026.
• TTM net income of about ₩4.8B is positive despite the operating loss, and the data does not explain the gap.
• Cash of about ₩8.6B is set against borrowings of ₩10B, and liabilities to equity is 32.2%.
• Filings show a buyback trust contract, a share cancellation decision and a corporate value-up plan, and the foreign ownership stake is about 1.1%.

What to watch

• The half-year and full-year results, especially whether operating income returns to profit and free cash flow improves.
• Completion details of the buyback trust and share cancellation, and how the announced value-up plan is carried out.
• News on the Hamsoa Pharmaceutical partnership and FSMP business, which the data does not show as financially quantified.